Study of the involvement of pancreastatin in the physiopathology of diabetes mellitus associated with nonsecreting pituitary adenomas

Hormone and Metabolic Research

Volumn 44, Issue 11, 2012, Pages 861-865

  Prevost G ^a,b   Eas, F ^a   Duparc, C ^b   Cauliez, B ^c   Laquerriere A ^c   Freger P ^c   Lefebvre, H ^a,b   Kuhn, J M ^a,b  

^a Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

diabetes mellitus; nonsecreting pituitary adenomas; pancreastatin

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT; PANCREASTATIN;

ACTH SECRETING ADENOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC DIET; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; INSULIN TREATMENT; MALE; NONSECRETING PITUITARY ADENOMAS; OPEN STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; TRANSSPHENOIDAL SURGERY;

AGED; AGED, 80 AND OVER; DIABETES COMPLICATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC HORMONES; PITUITARY NEOPLASMS;

RODENTIA;

EID: 84867336668     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1321796     Document Type: Article

References (32)

1. Clayton R. N., Raskauskiene D., Reulen R. C., Jones P. W. Mortality and morbidity in Cushings disease over 50 years in Stoke-on Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab: 2011; 96 632 642
2. Fieffe S., Morange I., Petrossians P., Chanson P., Rohmer V., Cortet C., Borson-Chazot F., Brue T., Delemer B. French Acromegaly registry Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol: 2011; 164 877 884
3. Resmini E., Minuto F., Colao A., Ferone D. secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol: 2009; 46 85 95
4. Passa P. Diabetes trends in Europe. Diabetes Metab: 2002; 18 S3 S8
5. Bonaldi C., Vernay M., Roudier C., Salanave B., Oleko A., Malon A., Castetbon K., Fagot Campagna A. A first national prevalence estimate of diagnosed and undiagnosed diabetes in France in 18- to 74-year-old individuals: the French nutrition and health survey 2006/2007. Diabet Med: 2011; 28 583 589
6. Buurman H., Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol: 2006; 154 753 758
7. Greenman Y., Stern N. Non-functioning pituitary adenomas. Best Pract Clin Endocrinol Metab: 2009; 23 625 638
8. Chanson P. Gonadotroph pituitary adenomas. Ann Endocrinol: 2000; 61 258 268
9. Andersen M., Ganc-Petersen J., Jorgensen J. O., Mellemkjaer S., Petersen P. H., Blaabjerg O., Hagen C. Hypersecretion of the alpha-subunit in clinically non-functioning pituitary adenomas: diagnostic accuracy is improved by adding alpha-subunit/gonadotropin ratio to levels of alpha subunit. Clin Invest Med: 2010; 33 E203 E212
10. Samejima N., Yamada S., Takada K., Sano T., Ozawa Y., Shimizu T., Usui M., Shishiba Y. Serum alpha-subunit levels in patients with pituitary adenomas. Clin Endocrinol: 2001; 54 479 484
11. Deftos L. J., OConnor D. T., Wilson C. B., Fitzgerald P. A. Human pituitary tumors secret chromogranin A. J Clin Endocrinol Metab: 1989; 68 869 872
12. Huttner W. B., Benedum U. M. Chromogranin A and pancreastatin. Nature: 1987; 325 305
13. Funakoshi S., Tamamura H., Ohta M., Yoshizawa K., Funakoshi A., Miyasaka K., Tateishi K., Tatemoto K., Nakano I., Yajima H., Fujii N. Isolation and characterization of a tumor-derived human pancreastatin-related protein. Biochem Biophys Res Commun: 1989; 164 141 148
14. Sanchez-Margalet V., Gonzalez-Yanes C. Pancreastatin inhibits insulin action in rat adipocytes. Am J Physiol Endocrinol Metab: 1998; 275 1055 1060
15. Lloyd R. V., Jin L., Qian X., Scheithauer B. W., Young W. F., Davis D. H. Analysis of the chromogranin A post-translational cleavage product pancreastatin and the prohormone convertases PC2 and PC3 in normal and neoplastic human pituitaries. Am J Pathol: 1995; 146 1188 1198
16. Jin L., Scheithauer B. W., Young W. F., Davis D. H., Klee G. G., Lloyd R. V. Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression. Am J Pathol: 1996; 148 2057 2066
17. Efendic S., Tatemoto K., Mutt V., Quan C., Chang D., Ostenson C. G. Pancreastatin and islet hormone release. Proc Natl Acad Sci USA: 1987; 84 7257 7260
18. Gonzalez-Yanes C., Sanchez-Margalet V. Pancreastatin, a chromogranin A-derived peptide, inhibits insulin-stimulated glycogen synthesis by activating GSK-3 in rat adipocytes. Biochem Biophys Res Commun: 2001; 89 282 287
19. Tatemoto K., Efendic S., Mutt V., Makk G., Feistner G. J., Barchas J. D. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature: 1986; 324 476 478
20. Sanchez-Margalet V., Gonzales-Yanes C., Najib S., Santos-Alvarez J. Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin. Regul Peptides: 2010; 161 8 14
21. Ahren B., Lindskog S., Tatemoto K., Efendic S. Pancreastatin inhibits insulin secretion and stimulates glucagon secretion in mice. Diabetes: 1988; 37 281 285
22. Gonzales-Yanes C., Sanchez-Margalet V. Pancreastatin modulates insulin signaling in rat adipocytes: mechanism of cross-talk. Diabetes: 2000; 49 1288 1294
23. Gayen J. R., Saberi M., Schenk S., Biswas N., Vaingankar S. M., Cheung W. W., Najjar S. M., OConnor D. T., Bandyopadhyay G., Mahata S. K. A novel pathway of insulin sensitivity in chromogranin A null mice, a crucial role for pancreastatin in glucose homeostasis. J Biol Chem: 2009; 284 28498 28509
24. OConnor D. T., Cadman P. E., Smiley C., Salem R. M., Rao F., Smith J., Funk S. D., Mahata S. K., Wen G., Taupenot L., Gonzalez-Yanes C., Harper K. L., Henry R. R., Sanchez-Margalet V. Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab: 2005; 90 5414 5425
25. Funakoshi A., Tateishi K., Shinozaki H., Matsumoto M., Wakasugi H. Elevated plasma levels of pancreastatin (PST) in patients with non-insulin-dependent diabetes mellitus (NIDDM). Regul Peptides: 1990; 30 159 164
26. Sanchez-Margalet V., Lobon J. A., Gonzales A., Escobar-Jimenez F., Goberna R. Increased plasma pancreastatin-like levels in gestational diabetes. Diabetes Care: 1998; 21 1951 1954
27. Heaney A. P., Curry W. J., Pogue K. M., Armstrong V. L., Mirakhur M., Sheridan B., Johnston C. F., Buchanan K. D., Atkinson A. B. Immunohistochemical evaluation of the post-translational processing of chromogranin A in human pituitary adenomas. Pituitary: 2000; 3 67 75
28. Jin L., Kulig E., Qian X., Scheithauer B. W., Young W. F., Davis D. H., Seidah N. G., Chretien M., Llyod R. V. Distribution and regulation of proconvertases PC1 and PC2 in human pituitary adenomas. Pituitary: 1999; 1 187 195
29. Gussi I. L., Young J., Baudin E., Bidart J. M., Chanson P. Chromogranin A as serum marker of pituitary adenomas. Clin Endocrinol: 2003; 59 644 648
30. Tadeishi K., Funakoshi A., Wakasugi H., Iguchi H., Shinozaki H., Abe M., Funakoshi S., Tamamura H., Yajima H., Matsuoka Y. Plasma pancreastatin-like immunoreactivity in various diseases. J Clin Endocrinol Metab: 1989; 69 1305 1308
31. Tadeishi K., Miyasaka K., Shinozaki H., Funakoshi S., Matsuoka Y., Funakoshi A. Pancreastatin like immunoreactivity in urine. J Clin Endocrinol Metab: 1990; 71 842 845
32. Pornet C., Bourdel-Marchasson I., Lecomte P., Eschwège E., Romon I., Fosse S., Assogba F., Roudier C., Fagot-Campagna A. ENTRED Scientific Committee Diabetes Metab: 2011; 37 152 161